THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era. Thursday, March 19, 2026

COMPOUND WATCH

Retatrutide (Reta) [Phase 3] — TRIUMPH-4 holds: 28.7% mean weight loss at 68 weeks (~71 lbs) at highest dose. Seven Phase 3 trials running in 2026 across T2D, sleep apnea, MASH, and cardiovascular outcomes. FDA approval filing expected late 2026; decision likely 2027. TikTok has banned searches and hashtags related to retatrutide — demand signal, not a safety signal (more in Signal vs. Noise). Meanwhile, GenoGenix was caught repackaging retatrutide — an unapproved compound — under unsanitary conditions. Three patients went to the ER. Full breakdown in Vendor Signal and Regulatory Radar.

Tirzepatide [Phase 3] — The compounding arbitrage window is getting squeezed from both sides: FDA enforcement is tightening the supply floor, and Lilly's $449/month Employer Connect price (fixed, through 15+ administrators, bypassing PBMs entirely) is cutting into the premium ceiling. Novo estimated 1 million people were on compounded GLP-1s last year — that number is under active assault from both directions simultaneously. Note: Novo guided for 5–13% sales decline in 2026, injectable Wegovy plateauing as growth shifts to oral semaglutide. NVO is down 52% over the past year. A weakening Novo is less able to sustain legal and lobbying pressure against compounders — watch whether their enforcement posture shifts with their financials.

Orforglipron [Phase 3] — April FDA decision window. Phase 3 data: 9.2% weight loss vs. 5.3% for oral semaglutide in head-to-head T2D trials. For context: oral Wegovy hit 57,000 US prescriptions by mid-February — described by IQVIA/RBC as one of the fastest drug launches ever. Orforglipron enters a market that has already demonstrated it will absorb an oral GLP-1 at scale. The question is price, not demand. If approved at or below $349/month, reassess your injectable compounding spend. LLY fell 5% to ~$937 on March 17 on regulatory uncertainty and HSBC downgrade — but Mounjaro generated $7.41B in Q4 alone (+110% YoY). The stock is being repriced, not the drug.

Aleniglipron [Phase 2] — Structure Therapeutics' ACCESS II topline data (March 16): 16.3% placebo-adjusted weight loss at 180mg and 16.0% at 240mg at 44 weeks, no plateau observed. Leerink Partners called it "best-in-class." GPCR +6%. End-of-Phase 2 FDA meeting Q2 2026; Phase 3 initiation 2H 2026. The oral pill to watch after orforglipron.

BPC-157 [Animal / Anecdotal — ZERO human RCTs] — Still being self-injected by hundreds of thousands under the "Wolverine Stack" label alongside TB-500. The rat data on tendon and gut healing remains the entire scientific basis. One Phase 2 human trial now recruiting (see Trial Tracker). Inject with that knowledge.

GLP-1 + Brain Metastases [Observational] — JAMA Network Open: 151 hospitals, 2018–2024, n=19,000+ cancer patients with T2D and brain metastases. GLP-1 users were ~37% less likely to die over 3 years vs. non-users. Effect consistent across lung, breast, and melanoma, and across semaglutide, dulaglutide, liraglutide, and tirzepatide. GLP-1 users also outperformed SGLT2 and DPP-4 inhibitor users — suggesting a GLP-1-specific mechanism, not just metabolic control. Observational only. No RCT. But 37% is not a rounding error.

VENDOR SIGNAL

[Flagged] — GenoGenix: The most significant compounding safety event in months. FDA found bacterial endotoxin contamination in unopened GenoGenix vials from the same lot linked to three ER visits — symptoms: low blood pressure, uncontrollable shaking, shivers, body aches. Manufacturing violations: unsanitary conditions, personnel failing to disinfect materials, aseptic processing with exposed skin, facility design compromising cleanroom integrity. GenoGenix was also repackaging semaglutide, tirzepatide, and retatrutide (unapproved), and compounding 5-Amino-1MQ and NAD+ — both ineligible for 503B compounding exemptions. If you have GenoGenix product in your fridge, stop using it.

[COA Only] — 30 telehealth companies: FDA sent 30 warning letters today to smaller telehealth operators over compounded GLP-1 products — following prior letters to Hims & Hers and MedisourceRx. Alleged violations: false/misleading claims, implying compounded products are equivalent to approved medicines, obscuring sourcing. No independent HPLC data exists for most of these platforms. COA-only sourcing from any of these operators should be treated as [Unverified] until independent testing confirms purity.

No Finnrick rating changes or new Janoshik results in today's data. Worth flagging: the GenoGenix contamination was caught by FDA inspection, not independent community testing. That's the gap. Check finnrick.com before your next order. The 15–20% COA discrepancy rate in this market isn't theoretical — it's what happens when the only quality check is the seller's own paperwork.

The GenoGenix case is the argument for independent endotoxin testing made in human terms. Three people went to the ER. The vial was unopened. The lot was contaminated. This is what "COA Only" looks like when it fails.

TRIAL TRACKER

[NCT07437547] BPC-157 — Phase 2, Acute Hamstring Muscle Strain | Recruiting | Started Feb 2026 First controlled human study of BPC-157 for musculoskeletal injury — the exact application driving most self-injection. Recruiting now. Results won't come fast, but the trial's existence is itself a signal: the compound is finally being tested in humans under controlled conditions. If you're injecting BPC-157 for tendon or muscle repair, you are currently ahead of the published science. That's your risk to own.

[NCT07357415] Retatrutide — Phase 3, Obesity/Overweight (No T2D) | Recruiting | Started Jan 2026 Isolates the obesity-only population — critical for FDA labeling. TRIUMPH-4 showed 28.7% weight loss at 68 weeks. This trial answers whether that holds without diabetes as a comorbidity. Approval filing expected late 2026. If you're sourcing gray-market reta now, you're using a compound with strong Phase 3 signals but zero regulatory standing anywhere in the world.

[NCT06632444] Survodutide — Phase 3, MASH/Liver Fibrosis (LIVERAGE™) | Recruiting | Started Sep 2024 GLP-1/glucagon dual agonist running two simultaneous Phase 3 MASH trials plus a cardiovascular outcomes trial. Not yet on most biohackers' radar. Watch the LIVERAGE readout for the first signal on whether glucagon co-agonism adds meaningful liver benefit over GLP-1 alone.

PRI-002 [Phase 2, Alzheimer's] — Priavoid oral all-d-peptide: Initial safety data presented at AD/PD 2026 — first 90 participants, 24 weeks, zero treatment-related ARIA signal. Compare: donanemab (ARIA-E: 24%), lecanemab (ARIA-E: 12.6%). DSMB recommended continuation without further ARIA monitoring across 304 participants at 38 sites in 6 European countries. Early, but a clean safety read for a peptide-based CNS compound. Relevant if you're tracking nootropic peptides.

ASC39 [Preclinical → IND Q3 2026] — Ascletis oral amylin receptor agonist: Head-to-head vs. eloralintide: EC50 for hAMY1R of 21.4 pM (ASC39) vs. 21.2 pM (eloralintide) — essentially identical potency, 64-fold selective for hAMY1R over hCTR. IND submission to FDA expected Q3 2026. The amylin mechanism is distinct from GLP-1 — watch this as a potential stacking target once human data exists.

THE ODDS

Retatrutide FDA approval by end of 2026: 22% probability — This is the number to anchor against if you're currently sourcing gray-market reta. The market is pricing an ~80% chance that reta remains unapproved through 2026. That's not pessimism — that's the base rate for a compound with a late-2026 filing target and a 2027 decision window. If you're injecting reta now, you're 12–18 months ahead of any regulatory standing, minimum. Plan your sourcing horizon accordingly.

Inflation above 3% in 2026: 92% probability ($138K volume) — Compounding pharmacy prices don't come down in this environment. The $200–500/month compounder cost for tirzepatide or semaglutide has structural upward pressure: labor, API costs, overhead. The deflationary forces — Lilly's $449/month Employer Connect price and India's incoming generic semaglutide at ~$36–48/month (Rs 3,000–4,000, down 75% from current Indian pricing) — are real, but they're not hitting your compounder's invoice yet.

US recession by end of 2026: 32% probability ($690K volume) — Below the threshold where sourcing behavior shifts meaningfully. Working rule of thumb from this newsletter: watch for 40%+ before expecting a material move toward QSC/SRY orders (Chinese gray-market API suppliers) and away from compounders. At 32%, most readers are still price-sensitive but not panic-sourcing. If recession odds drift above 40% in the next 30 days — plausible given HSBC's LLY downgrade and broader pharma repricing — expect more gray-market volume and more pressure on compounders to hold prices.

The macro translation: Near-certain inflation + sub-40% recession odds = the gray-market stays large, compounders hold pricing power, and the $449 Lilly direct-to-employer program becomes the most interesting competitive pressure point to watch. The FDA's 30 warning letters today are the supply-side squeeze; Lilly's price cut is the demand-side pull. Both are working against the compounding channel simultaneously. The 22% reta approval odds are the ceiling on how much regulatory risk you're carrying if you're sourcing it now.

SIGNAL VS. NOISE

SIGNAL: FDA's 30 warning letters + GenoGenix ER visits. Structural escalation, not a one-off. The FDA previously targeted Hims & Hers and MedisourceRx — the biggest names. Today's 30 letters hit smaller operators. The enforcement is moving down-market, which means the next wave hits the platforms your Telegram group recommends. GenoGenix's endotoxin contamination and three ER visits give the FDA a concrete human-harm narrative to justify continued action. Sourcing decisions made in the next 30–60 days should account for a meaningfully higher probability that your current telehealth platform receives a warning letter.

SIGNAL: GLP-1 discontinuation and cardiovascular risk (VA study, March 18). People who stop GLP-1 drugs may not only regain weight — they may also increase cardiovascular risk, per a new VA patient study. This is directly relevant if you're cycling on/off compounded tirzepatide due to supply gaps or the current enforcement squeeze. The cost of stopping is not just the weight you regain. Full paper not yet published; no specific hazard ratio available. Watch for it — this changes the risk calculus for anyone treating supply disruptions as a reason to pause.

SIGNAL: India generic semaglutide launching this week. Semaglutide patent expires March 20–24 in India. At least seven manufacturers approved (Sun Pharma, Dr. Reddy's, Zydus, Natco, Alkem, Lupin co-marketing). Price expected to drop 75% — from Rs 10,000–12,000/month to Rs 3,000–4,000/month (~$36–48 USD). Doesn't immediately change US sourcing, but establishes a global price floor that will pressure every channel above it. Watch whether Indian generic API starts appearing in US gray-market supply chains within 6–12 months.

SIGNAL: BMI threshold equity problem (STAT News, March 17). The FDA's ≥27 BMI threshold for semaglutide eligibility was derived from a trial that was 84% white, 8% Asian. South Asian "thin-fat phenotype" means cardiovascular risk accumulates at BMI <25 — ~43% of Indian adults are metabolically obese despite BMI <25. A meta-analysis found GLP-1s reduced cardiovascular events nearly twice as effectively in Asian patients as in white patients. Indian cardiologists recommend waist circumference, not BMI alone, as the prescribing criterion. Relevant to anyone advising on dosing eligibility for non-standard BMI profiles or sourcing for patients who don't meet the standard threshold.

SIGNAL: BPL-003 Phase 2a published in peer-reviewed journal. AtaiBeckley's intranasal mebufotenin benzoate — a synthetic tryptamine structurally related to 5-MeO-DMT, delivered nasally — produced mean MADRS reduction of 12.6 points by Day 2 in TRD patients, sustained through Day 85. 54.5% response rate, 63.6% remission rate at one or more timepoints. No serious adverse events. Phase 3 initiation Q2 2026. The peer-reviewed publication matters — this isn't a press release. Novel nasal delivery mechanism for a psychedelic-adjacent compound with rapid, durable antidepressant effects. Relevant if you're tracking CNS peptide-adjacent compounds.

NOISE: TikTok banning retatrutide hashtags. Platform moderation is a demand signal, not a supply or safety signal. TikTok banning reta searches tells you the compound is generating consumer interest — it tells you nothing about its safety, efficacy, or availability. The 28.7% Phase 3 weight loss data is the signal. The TikTok ban is the noise around it.

NOISE: "Wolverine Stack" media coverage. STV News profiling BPC-157 + TB-500 as a named trend is a lagging indicator. The biohacking community has been running this stack for years. Media attention at this stage means mainstream curiosity, not new science. The evidence grade hasn't changed: [Animal] for BPC-157, [Animal] for TB-500. The coverage doesn't upgrade the data.

REGULATORY RADAR

Today is the most significant single-day FDA enforcement action against the compounding channel since the Hims & Hers letters.

30 warning letters, telehealth companies, compounded GLP-1 products. Alleged violations: false/misleading claims, implying equivalence to approved medicines, obscuring sourcing. Enforcement explicitly moving from large platforms to smaller operators. The FDA will likely publish the recipient list — cross-reference against your current sourcing chain.

GenoGenix — most severe case. Violations: (1) Repackaging semaglutide, tirzepatide, and retatrutide. (2) Compounding 503B-ineligible substances: 5-Amino-1MQ and NAD+. (3) Manufacturing violations: unsanitary conditions, bacterial endotoxin contamination in unopened vials, personnel failing to disinfect, aseptic processing with exposed skin, facility design compromising cleanroom integrity. (4) Three patients directed to the ER — low blood pressure, uncontrollable shaking, shivers, body aches. Treat any GenoGenix product as [Flagged] until further notice.

UK parallel: MHRA has raided two separate facilities in the past six months. The National Pharmacy Association is calling for urgent legislative review of "research only" product sales. MHRA's head of borderlines stated they "disregard claims that products are for research purposes" if it is clear they are being used as medicines. The UK is approximately 12–18 months behind the US on enforcement trajectory — but the direction is identical.

RFK / peptide reclassification: No formal FDA rule has been issued. RFK's promise to end the "war on peptides" remains enforcement discretion only — not a regulatory change. BPC-157, TB-500, CJC-1295, Ipamorelin, and GHK-Cu remain Category 2. No Federal Register notice in today's data. Do not make sourcing decisions based on a promise that has not been formalized.

India generic semaglutide: Patent expiry March 20–24. Seven-manufacturer launch creates a new supply reality that will pressure US pricing channels over the next 12–24 months, even if it doesn't change your sourcing options this week.

WHAT TO WATCH

Now — immediately: If you have GenoGenix product, stop using it. Bacterial endotoxin contamination confirmed in an unopened vial from the same lot linked to three ER visits. This is not precautionary — it is post-incident.

March 20–24: India semaglutide patent expires. Watch for Zydus (Semaglyntm/Mashematm/Altermetm), Lupin (Semanext/Livarise), and Dr. Reddy's (Obeda) launch announcements. No immediate US sourcing impact, but establishes the global price floor.

When FDA publishes warning letter recipients: Cross-reference the list against every telehealth platform in your current sourcing chain. If your platform is on it, treat their products as [COA Only] at best until independent testing confirms purity.

April 2026: FDA decision window on orforglipron. If approved at or below $349/month self-pay, reassess your injectable compounding spend. A once-daily pill with 9.2% weight loss and no reconstitution changes the convenience calculus — and oral Wegovy's 57,000-prescription launch pace tells you the market will absorb it fast.

Q2 2026: Structure Therapeutics end-of-Phase 2 FDA meeting for aleniglipron. Phase 3 initiation decision follows. Best efficacy signal in the oral pipeline right now (16.3% placebo-adjusted weight loss, no plateau at 44 weeks).

Q3 2026: ASC39 IND submission to FDA (Ascletis oral amylin receptor agonist). First oral small molecule with eloralintide-like potency entering the clinic. Watch for IND acceptance as the trigger for Phase 1 enrollment.

Ongoing — recession odds: Currently 32%. If they cross 40% on Polymarket with volume above $1M, that's the threshold where gray-market sourcing behavior historically shifts. Not there yet.

Prediction scorecard: - March 16 prediction: Check tirzepatide formulation for B12 content. No new data today — still a standing recommendation. If your compounder adds B12 without your request, ask why and get the specific form in writing. - Q2 2026 orforglipron FDA approval: April decision window approaching. Watch for pricing announcement concurrent with approval — that number determines whether the compounding calculus changes. - Recession odds threshold at 40%: Currently 32%. Hypothesis unchanged.

The single line to carry into next week: The FDA is now sending warning letters to the small players — which means the enforcement map has expanded to cover most of the telehealth-to-compounding pipeline your community uses. The GenoGenix contamination gives regulators a human-harm narrative. The VA discontinuation study gives patients a reason not to cycle off. Both are working in the same direction: the cost of staying in the gray market is rising, and the cost of stopping is higher than you thought.

Reply to this email with what you're seeing on the ground — vendor changes, formulation shifts, compounder communications. This newsletter gets sharper with your signal in it.

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $15/month. Manage your subscription.